Science News About Clinical Research and Trials

Evidence-based practices for suicide prevention effectively reduced suicidal behaviors among adults seen for care in emergency departments.

An NIMH-supported study suggests that a brief self-association training program can extend the effects of a single ketamine infusion by shifting people’s negative self-beliefs.

The NIMH Healthy Research Volunteer Study aims to build a comprehensive, publicly accessible resource with a range of brain and behavioral data from healthy volunteers.

TMS can only directly stimulate the outermost layer of the brain, but NIMH researchers have found that mapping a person’s brain architecture may make it possible to guide TMS to deep brain targets.

A new study shows the use of a clinical decision support system to prompt the use of shared decision-making tools, such as handouts, may result in positive impacts on long-term cardiovascular health in patients with serious mental illness.

An analysis of clinical trial data shows that improvements in emotion regulation in youth at high risk for suicide who received dialectical behavior therapy (DBT) led to a reduction in self-harm behaviors.

NIMH is working to meet the urgent need for rapid-acting suicide prevention interventions by supporting research investigating the feasibility and safety of treatment protocols that have the potential to quickly reduce severe suicide risk in youth and adults.

In a project funded by the NIMH Small Business Technology Transfer program, researchers are investigating whether mobile technology can be used to create a passive monitoring system that can predict teens’ depressive symptoms and improve the quality of their care.

Carlos Zarate Jr., M.D., chief of the Experimental Therapeutics and Pathophysiology Branch within the NIMH Intramural Research Program, has been elected to the National Academy of Medicine.

Experts from the National Institute of Mental Health are available to speak on topics related to suicide and suicide prevention, including the warning signs of suicide, suicide prevention methods, trends in suicide rates, how to find mental health help and support, and the latest in suicide prevention research.

In a new paper, published in JAMA Psychiatry, NIMH looks forward, outlining the next stages in the Institute’s suicide prevention research priorities.

An innovative NIMH-funded trial shows that a receptor involved in the brain’s reward system may be a viable target for treating anhedonia (or lack of pleasure), a key symptom of several mood and anxiety disorders.

The use of right unilateral ultrabrief pulse (RUL-UB) electroconvulsive therapy (ECT) in combination with the antidepressant venlafaxine to treat depression in elderly patients is well tolerated and results in minimal neurocognitive side effects, according to a new NIH-funded study published in the American Journal of Geriatric Psychiatry.

In 2018, 11.4 million adults in the United States experienced a serious mental illness, such as schizophrenia-spectrum disorders, severe bipolar disorder, and severe depression.

NIH-funded research uses machine learning algorithm to predict individual response to a commonly-prescribed antidepressant.

Researchers have uncovered sex-based differences in the development of the hippocampus and amygdala—brain areas that have been implicated in the biology of several mental disorders that impact males and females differently.

NIMH awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis.

Mental health research center directors emerged from a recent meeting with a renewed commitment to help each other achieve their common mission – to transform care of children, adolescents and adults with severe psychiatric disorders.

FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.

A research team found nearly one-third of youth ages 10 to 12 years screened positive for suicide risk in emergency department settings, including those seeking help for physical concerns only.